Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 10, 2002Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -
-
Sep 9, 2002Insmed Announces Appointment of Mary Callan as Vice President of Corporate Development
-
Aug 19, 2002Insmed Announces Appointment of Vice President of Commercial Development
-
Jul 29, 2002Insmed Incorporated and Avecia Limited Announce Development and Manufacturing Agreement for SomatoKine
-
Jul 26, 2002Insmed Incorporated Reports Second Quarter Results
-
Jul 25, 2002Insmed Incorporated Invites You to Join Its 2nd Quarter Earnings Conference Call On: Tuesday, July 30, 2002 at 9:00 a.m. EDT
-
Jul 18, 2002Insmed Presents Lead Drug Candidates At ENDO 2002, The 84th Annual Meeting of the Endocrine Society
-
Jul 17, 2002Insmed Incorporated Receives Orphan Drug Designation for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome -Laron Syndrome- and Inititates Clinical Study
-
Jul 8, 2002Insmed Incorporated Announces Investor Update Conference Call; Tuesday, July 9, 2002, at 9:00 a.m. ET - 8:00 a.m. CT
-
Jun 17, 2002Insmed Reports Data On Insulin Sensitizing Drug At American Diabetes Associations Annual Meeting
